ClinicalTrials.gg
CompletedNCT00043862(SCLC)Updated May 31, 2017

The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

A Phase 2 interventional study of topotecan in Lung Cancer, Small Cell and Small Cell Lung Cancer, sponsored by GlaxoSmithKline. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-31.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.

Enrollment
12th of 28
60 · median 44
Started
2002
with 1 other
Phase 2
11 of 29
1 open now
Registered
6th of 29
by date
Lead sponsor
7 of 29
GlaxoSmithKline

Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2002, is one of 11 in phase 2, and was the 6th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About topotecan

Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing topotecan in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug that may enhance the effects of radiation therapy. Study patients will receive two additional courses of the standard chemotherapy combination after completing radiation therapy.

03

Conditions studied

  • Lung Cancer, Small Cell
  • Small Cell Lung Cancer

Keywords

  • Hycamtin
  • oral
  • Radiation Sensitization
  • Small Cell Lung Cancer
  • newly diagnosed
  • limited stage
  • topotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with no prior radiotherapy. Patients are allowed to have had a resection or .
  • Women of must have a negative serum pregnancy test at the study screening visit.
  • Patients must give written to participate in the study.
  • Patients must be able to take oral medication.
  • Patients should be completely recovered from recent surgery.
  • Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.
  • Patients must be evaluated by the radiation oncologist prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • Extensive Stage SCLC.
  • Women who are pregnant or lactating.
  • Use of an drug within 30 days prior to the first dose of study medication.
  • Any medically/ active infection.
  • Symptoms of the SCLC spreading to the brain.
  • Patients with limited stage SCLC who have undergone complete resection with no prior to starting chemotherapy.
  • Severe medical problems, unrelated to SCLC, that would limit the patient's full ability to follow all study rules and procedures, or that would expose the patient to extreme risk.
  • Other ongoing, immunotherapy or radiotherapy being administered at the time as study participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Response rate

Secondary outcomes

  1. Time to Progression, response duration, survival, quantitative and qualitative assessment of tolerability

07

Study locations

31 sites
  • GSK Investigational Site
    Phoenix, Arizona 85013 - 4496, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Bakersfield, California 93309, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Los Angeles, California 90057, United States
  • GSK Investigational Site
    Gainesville, Florida 32610, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46260, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536-0098, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71103, United States
  • GSK Investigational Site
    Scarborough, Maine 04074, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01107, United States
  • GSK Investigational Site
    Duluth, Minnesota 55805, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Robbinsdale, Minnesota 55422, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    St. Louis, Montana 63110, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87109, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Akron, Ohio 44304, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Toledo, Ohio 43614-5809, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Green Bay, Wisconsin 54301, United States
  • GSK Investigational Site
    La Crosse, Wisconsin 54601, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • GSK Investigational Site
    Wausau, Wisconsin 54401, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002 and a primary completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2002
First posted
Aug 15, 2002
Start
Aug 2002
Primary completionActual
Nov 2005
Last update
May 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00043862
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 15, 2002
Start date
Aug 2002
Primary completion
Nov 2005
Last update
May 31, 2017

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Topotecan

Start the discussion